drugset / Trial / NCT04958252

A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated

NCT04958252

Phase 1 Completed 56 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objectives of this trial are to investigate safety and tolerability of BI 1569912 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses. Secondary objective is the exploration of pharmacokinetics (PK) of BI 1569912.

Timeline

Start
2021-08-05
Primary completion
2023-10-30
Completion
2023-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1569912 Unknown 2.5 mg Oral
Subject BI 1569912 Unknown 5 mg Oral
Subject BI 1569912 Unknown 10 mg Oral
Subject BI 1569912 Unknown 20 mg Oral

Indications

No indication recorded.